Abilita Bio, Inc. is a San Diego-based biotechnology startup that is revolutionizing the drug discovery process founded by Mauro Mileni. With a recent $7.5 million investment from Two Bear Capital, Abilita Bio is on a mission to grant access to medically important targets that were previously considered "intractable" or "undruggable." The company provides a unique opportunity to directly use purified proteins for discovery processes and remove multi-span membrane protein (MMP)-specific limitations in many discovery approaches, boosting the probability of developing drugs that would otherwise remain elusive. 

Abilita Bio's strength lies in its EMP™ technology, which is based on the principles of directed evolution. Enabled Membrane Proteins (EMPs™) are stability and expression enhanced variants that enable the discovery and optimization of drug candidates. With this innovative technology, Abilita Bio is poised to make a significant impact in the biotech industry and potentially bring life-changing drugs to market.